Futura Medical has presented detailed data from the pivotal FM57 Phase III Erectile Dysfunction (ED) study in a webcast. The headline results were released in December 2019 (see Update note). These showed no statistical difference between the three GTN dose arms and the DermaSys (placebo) arm, yet a strongly statistical difference vs baseline. These results suggested that this specific DermaSys formulation, now known as MED3000, was effective in its own right.
